Skip to content

Oral Metronidazole Administered Intravaginally for the Treatment of Bacterial Vaginosis: A Non-inferiority Randomized Controlled Trial

Efficacy and Safety of Oral Metronidazole Administered Intravaginally for the Treatment of Bacterial Vaginosis: A Non-inferiority Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250218011
Enrollment
32
Registered
2025-02-18
Start date
2025-06-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Women aged 18-45 diagnosed with bacterial vaginosis based on Amsel criteria and Nugent score, not an immunocompromised hots. Bacterial vaginosis, metronidazole, vaginal administration,oral formulation, efficacy and safety

Interventions

Participants in this group will receive oral metronidazole 800 mg (2 tablets of 400 mg each) administered intravaginally (inserted into the vagina) once daily before bedtime for 7 consecutive days.,Pa
Experimental Other,Active Comparator Other
Intravaginal group,Oral group

Sponsors

Buri Ram Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Women aged 18-45 years. 2. Diagnosed with Bacterial Vaginosis (BV) based on Amsel criteria (at least 3 out of 4 criteria: abnormal vaginal discharge, vaginal pH > 4.5, positive whiff test, and presence of clue cells >20%). 3. Willing to provide informed consent and comply with the study protocol.

Exclusion criteria

Exclusion criteria: 1. Known allergy or hypersensitivity to metronidazole or nitroimidazole derivatives. 2. Pregnant, planning to become pregnant during the study, or breastfeeding. 3. Presence of other vaginal infections (e.g., vulvovaginal candidiasis or Trichomonas vaginalis infection). 4. Use of antibiotics or antifungal medications within 14 days prior to enrollment. 5. Chronic medical conditions such as porphyria, severe liver disease, epilepsy, severe hematological disorders, or immunocompromised status. 6. Regular alcohol consumption or inability to abstain from alcohol during the study and for 48 hours after the last dose of metronidazole. 7. Use of medications that may interact with metronidazole (e.g., warfarin, lithium, disulfiram).

Design outcomes

Primary

MeasureTime frame
clinical cure from signs and symptoms improvement 14 days yes,no/ clinical and microscopic assessment

Secondary

MeasureTime frame
adverse effects of the treatment 14 days and 1 month yes,no/interview,recurrence rate 1 month yes,no/ clinical and microscopic assessment,patient satisfaction 1 month satisfaction score

Countries

Thailand

Contacts

Public ContactSiriphen Uengphinitphong

Buri Ram Hospital

mail2siriphen@gmail.com044625091

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026